Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Rimegepant in Migraine
NCT03266588Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rimegepant in migraine, sponsored by Pfizer. Primary endpoints: Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period at 12 weeks and Number of Participants With Clinically Significant Laboratory Abnormalities During the Treatment Period at 12 weeks. Started Aug 2017; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03266588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266588.